- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02582866
A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
A Multicenter, Open-label, Follow-up Study to Assess the Long-term Use of Lacosamide (Flexible Dose From 200 to 600 mg/Day) Used as Monotherapy in Subjects Who Completed SP0994 and Received Lacosamide Monotherapy Treatment
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Blagoevgrad, Bulgaria
- Sp1042 805
-
Pazardzhik, Bulgaria
- Sp1042 807
-
Sofia, Bulgaria
- Sp1042 811
-
-
-
-
-
Helsinki, Finland
- Sp1042 205
-
Kuopio, Finland
- Sp1042 207
-
-
-
-
-
Nancy, France
- Sp1042 236
-
-
-
-
-
Altenburg, Germany
- Sp1042 263
-
Bad Neustadt An Der Saale, Germany
- Sp1042 265
-
Leipzig, Germany
- Sp1042 269
-
Marburg, Germany
- Sp1042 256
-
Osnabruck, Germany
- Sp1042 259
-
-
-
-
-
Asaka, Japan
- Sp1042 831
-
Kagoshima, Japan
- Sp1042 834
-
Kamakura, Japan
- Sp1042 844
-
Nagoyashi, Japan
- Sp1042 835
-
Okayama, Japan
- Sp1042 837
-
Sapporo, Japan
- Sp1042 847
-
-
-
-
-
Daegu, Korea, Republic of
- Sp1042 521
-
Daejeon, Korea, Republic of
- Sp1042 518
-
Seoul, Korea, Republic of
- Sp1042 517
-
Seoul, Korea, Republic of
- Sp1042 519
-
-
-
-
-
Riga, Latvia
- Sp1042 751
-
-
-
-
-
San Luis Potosi, Mexico
- Sp1042 547
-
-
-
-
-
Pasig, Philippines
- Sp1042 672
-
Quezon, Philippines
- Sp1042 676
-
-
-
-
-
Katowice, Poland
- Sp1042 340
-
Lublin, Poland
- Sp1042 342
-
Warszawa, Poland
- Sp1042 343
-
-
-
-
-
Bucuresti, Romania
- Sp1042 576
-
Iasi, Romania
- Sp1042 570
-
Targu Mures, Romania
- Sp1042 572
-
-
-
-
-
Kazan, Russian Federation
- Sp1042 387
-
Kazan, Russian Federation
- Sp1042 389
-
Moscow, Russian Federation
- Sp1042 401
-
Novosibirsk, Russian Federation
- Sp1042 392
-
Saint Petersburg, Russian Federation
- Sp1042 397
-
Saint Petersburg, Russian Federation
- Sp1042 400
-
-
-
-
-
Goteborg, Sweden
- Sp1042 440
-
Linköping, Sweden
- Sp1042 442
-
Stockholm, Sweden
- Sp1042 438
-
-
-
-
-
Aarau, Switzerland
- Sp1042 651
-
Biel, Switzerland
- Sp1042 654
-
Lugano, Switzerland
- Sp1042 653
-
-
-
-
-
Chernihiv, Ukraine
- Sp1042 622
-
Kharkov, Ukraine
- Sp1042 626
-
Odesa, Ukraine
- Sp1042 625
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- An Institutional Review Board /Institutional Ethics Committee approved written Informed Consent Form (ICF) is signed and dated by the subject or by the parent(s) or legal representative. The ICF or a specific Assent form, where required, will be signed and dated by minors
- Subject/legal representative is considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgment of the investigator
- Subject has completed the Termination Visit of SP0994 [NCT01465997] and has been treated with lacosamide monotherapy
Exclusion Criteria:
- Subject is receiving any investigational drugs or using any experimental devices in addition to lacosamide (LCM)
- Subject experienced a seizure at the 3rd target dose (i.e. LCM 600 mg/day) during SP0994
- Subject required another Anti Epileptic Drug (AED) for the treatment of seizures
- Subject meets a "must" withdrawal criteria for SP0994
- Subject is experiencing an ongoing Serious Adverse Event from SP0994
- Female subject who is pregnant or nursing, and/or a woman of childbearing potential who is not surgically sterile, 2 year postmenopausal or does not practice one highly effective method of contraception, unless sexually abstinent, for the duration of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lacosamide
Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day. Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks. |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Experiencing Any Adverse Events (AEs) Reported Spontaneously by the Subject and/or Caregiver or Observed by Investigator
Time Frame: From Visit 1 (Week 0) to Final Visit (up to Week 158)
|
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
An AE could, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication.
|
From Visit 1 (Week 0) to Final Visit (up to Week 158)
|
Percentage of Participants That Withdrew Due to Adverse Events (AEs)
Time Frame: From Visit 1 (Week 0) to Final Visit (up to Week 158)
|
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication.
An AE could, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication.
|
From Visit 1 (Week 0) to Final Visit (up to Week 158)
|
Percentage of Participants Experiencing Any Serious Adverse Events (SAEs) Reported Spontaneously by the Subject and/or Caregiver or Observed by Investigator
Time Frame: From Visit 1 (Week 0) to Final Visit (up to Week 158)
|
A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:
|
From Visit 1 (Week 0) to Final Visit (up to Week 158)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: UCB Cares, +1 844 599 2273 (UCB)
Publications and helpful links
General Publications
- Ben-Menachem E, Dominguez J, Szasz J, Beller C, Howerton C, Jensen L, McClung C, Roebling R, Steiniger-Brach B. Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open-label trial. Epilepsia Open. 2021 Sep;6(3):618-623. doi: 10.1002/epi4.12522. Epub 2021 Aug 2.
- Inoue Y, Liao W, Wang X, Du X, Tennigkeit F, Sasamoto H, Osakabe T, Hoshii N, Yuen N, Hong Z. Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial. Epilepsy Res. 2021 Oct;176:106705. doi: 10.1016/j.eplepsyres.2021.106705. Epub 2021 Jun 29.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP1042
- 2015-001549-96 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Lacosamide
-
Seoul National University HospitalDongsan Medical Center; Konkuk UniversityCompleted
-
University of California, San FranciscoSan Francisco VA Health Care SystemCompletedAlcohol Use DisorderUnited States
-
UCB Biopharma S.P.R.L.Completed
-
UCB Biopharma S.P.R.L.CompletedHealthy VolunteersUnited Kingdom
-
UCB PharmaCompleted
-
Overseas Pharmaceuticals, Ltd.Beijing Capton Pharmaceutical Technology Development Co., LTDNot yet recruiting
-
UCB Pharma SAUCB Japan Co. Ltd.CompletedEpilepsy | Partial Onset SeizuresChina, Japan
-
UCB Pharma SACompletedHealthy VolunteersUnited Kingdom
-
UCB Biopharma SRLRecruitingEpilepsy | Electroencephalographic Neonatal SeizuresUnited States, Australia, Canada
-
UCB BIOSCIENCES, Inc.CompletedEpilepsyUnited States, Australia, Brazil, Bulgaria, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Taiwan